mRNA-1273.211

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), ModernaTX, Inc.

Conditions

COVID-19SARS-CoV-2

Phase 1

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

CompletedNCT04889209

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19

Start: 2021-05-28End: 2023-06-16Updated: 2025-04-20

Phase 2

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

CompletedNCT04927065

ModernaTX, Inc.SARS-CoV-2

Start: 2021-05-28End: 2023-11-17Updated: 2025-02-28

Related Papers

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.

2025-10-011 citations

P-102. Six-Month Safety, Durability, and Cross-Neutralization of the SARS-CoV-2 XBB.1.5-Containing Vaccine

Open Forum Infectious Diseases2025-01-29

The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.

2024-08-0111 citations

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Nature Medicine2023-08-3168 citations

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.

2023-08-2320 citations

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.

2023-07-1118 citations

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.

2022-10-06121 citations

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

New England Journal of Medicine2022-09-16635 citations

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.

2022-06-20139 citations

Homologous and Heterologous Covid-19 Booster Vaccinations

New England Journal of Medicine2022-01-26603 citations